Myeloproliferative Neoplasms | Specialty

Ruxolitinib/Pegylated Interferon Alpha 2a Reduces Spleen Length in Myelofibrosis

January 23rd 2023

First-line ruxolitinib plus pegylated interferon alpha 2a demonstrated durable spleen volume reduction in patients with myelofibrosis.

TP-3654 Showcases Early Signs of Tolerability, Clinical Activity in Myelofibrosis

January 17th 2023

The PIM1 kinase inhibitor TP-3654 was well tolerated and showcased preliminary signs of activity, including spleen volume reduction, symptom improvement, and broad cytokine reduction, in patients with myelofibrosis who were previously treated with or were ineligible for a JAK inhibitor.

Dr. Garcia on Future Expectations of Trials and Therapies in Myelofibrosis

January 16th 2023

Jacqueline S. Garcia, MD, discusses the future expectations of trials and therapies to improve outcomes in myelofibrosis.

Imetelstat Provides Durable Transfusion Independence in Lower-Risk MDS

January 4th 2023

Significant and durable transfusion independence was achieved with imetelstat vs placebo in patients with lower-risk myelodysplastic syndromes who were relapsed, refractory, or ineligible for erythropoiesis-stimulating agents, meeting the primary and a key secondary end point of the phase 3 IMerge trial.

Dr. Oh on the Anemia Benefit of Pacritinib in Myelofibrosis

December 23rd 2022

Stephen T. Oh, MD, PhD, discusses the anemia benefit of pacritinib in patients with myelofibrosis.

Dr. Rampal on the Importance of Clinical Trial Enrollment in Myelofibrosis

December 19th 2022

Raajit K. Rampal, MD, PhD, discusses the importance of clinical trial enrollment in patients with myelofibrosis.

Dr. Oh on Pacritinib in Myelofibrosis

December 19th 2022

Stephen T. Oh, MD, PhD, discusses the benefits of pacritinib in patients with myelofibrosis.

Dr. Palmer on Symptom Burden in Myelofibrosis With Thrombocytopenia

December 19th 2022

Jeanne M. Palmer, MD, discusses total symptom scores in patients with myelofibrosis with thrombocytopenia.

Thrombocytopenia Is Associated With Greater Symptom Burden in Myelofibrosis

December 14th 2022

Low platelet counts were associated with a greater severity of disease-related symptoms compared with low hemoglobin in patients with myelofibrosis, according to findings from a retrospective analysis of the phase 3 PERSIST-1 and PAC203 trials.

Unveiling Practice-Changing Data in CLL, GVHD, and MPNs: Drs Catherine Coombs, Nelli Bejanyan, and Aaron Gerds

December 13th 2022

Momelotinib Responses Upheld Through 48 Weeks in Patients With Anemic Myelofibrosis

December 12th 2022

Momelotinib elicited durable symptom, transfusion independence, and splenic responses through 48 weeks of treatment in patients with myelofibrosis who have anemia and previously received a JAK inhibitor.

Selinexor/Ruxolitinib Combo Reduces Spleen Volume in Myelofibrosis

December 11th 2022

The combination of selinexor and ruxolitinib significantly reduced spleen volume and total symptom score while achieving hemoglobin stabilization in an open-label dose-escalation/dose-expansion, phase 1 study of patients with treatment-naïve myelofibrosis.

Olverembatinib Benefit Holds Up in BCR-ABL1 T315I-Mutant, TKI-Resistant CML

December 10th 2022

Olverembatinib was found to uphold clinical benefit and continued to have an acceptable safety profile in patients with BCR-ABL1 T315I-mutant chronic myeloid leukemia -chronic phase or -acute phase that is resistant to TKIs.

EMA Accepts Marketing Authorization Application for Momelotinib in Myelofibrosis

December 2nd 2022

The European Medicines Agency has accepted a marketing authorization application for momelotinib as a treatment for patients with myelofibrosis.

Dr. Schiller on JAK Inhibitors in Myelofibrosis

December 2nd 2022

Gary J. Schiller, MD, discusses the benefits and challenges associated with JAK-directed therapies in the treatment of patients with myelofibrosis.

Dr. Mascarenhas on Advancements in the Treatment Landscape of Myelofibrosis

November 28th 2022

John O. Mascarenhas, MD, discusses current advancement in the treatment landscape of myelofibrosis.

Expanding Treatment Options Elevate Outcomes for Patients With Myelofibrosis

November 28th 2022

John Mascarenhas, MD, discusses the shifts from monotherapy to combination therapies in the evolving field of myelofibrosis care.

Dr. Rampal on the Future Research of CDK4/6 Inhibitors in MPNs

November 22nd 2022

Raajit K. Rampal, MD, PhD, discusses the future research of CDK4/6 inhibitors in myeloproliferative neoplasms.

Dr. Rampal on Pelabresib With or Without Ruxolitinib in Myelofibrosis

November 17th 2022

Raajit K. Rampal, MD, PhD, discusses the investigation of pelabresib with or without ruxolitinib in patients with myelofibrosis.

Dr. Schiller on Addressing Unmet Needs in Myelofibrosis Treatment

November 16th 2022

Gary J. Schiller, MD, discusses several areas of unmet need in myelofibrosis, and how to potentially address these challenges.